The FDA has cleared the first app that integrates glucose data with multiple daily injection (MDI) insulin dosing for people with diabetes.
The MiniMed Go Smart MDI system, from Medtronic Diabetes, is indicated for people with insulin-treated Type 1 or Type 2 diabetes aged 7 years and older who use injections and for those aged 2-6 years under adult supervision. It connects Medtronic’s InPen ‘smart insulin pen’ with Abbott’s Instinct continuous glucose sensor.
Features include real-time glucose data, dose calculations, missed dose alerts, and “actionable guidance,” according to a Medtronic statement. The app works with most major smartphones.
The system identifies missed meal doses or miscalculations by tracking rapid rises in glucose. It uses algorithms to detect consistent glucose trends that indicate food intake, along with personal settings and active insulin from previous doses to determine if a safe “correction” bolus is needed to bring glucose levels back into target range.
To find out more, CLICK HERE.
